First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor.

Imatinib, a tyrosine kinase inhibitor, is primarily used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The most common adverse events include peripheral edema, mild nausea, vomiting, diarrhea, myalgia, muscle cramps, and skin rash. In patients with GIST receiving imatinib therapy, routine laboratory tests typically reveal hematologic abnormalities such as decreased hemoglobin, erythrocyte, neutrophil, and platelet counts, alongside elevated hepatic transaminase levels. However, to our knowledge, no cases of imatinib-associated hypouricemia have been reported. Here, we present a case of hypouricemia temporally associated with adjuvant imatinib therapy in a patient with intestinal GIST. This case highlights the importance for clinicians to be aware of hypouricemia as a potential adverse event during imatinib therapy.